H. Lundbeck AS (STU:LDBA) Research & Development: €677 Mil (TTM As of Mar. 2026)


STU:LDBA H. Lundbeck AS STU:LDBA
68 GF Score
Price €5.75
GF Value €6.36
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is H. Lundbeck AS Research & Development?

H. Lundbeck AS STU:LDBA -2.46% 68 Research & Development is €677 Mil as of Mar. 2026. GuruFocus rates STU:LDBA with a GF Score™ of 68/100 and a GF Value™ of €6.36 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. H. Lundbeck AS's Research & Development for the three months ended in Mar. 2026 was €185 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €677 Mil.

H. Lundbeck AS  (STU:LDBA) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

H. Lundbeck AS Research & Development Related Terms

H. Lundbeck AS Research & Development Historical Data

* Premium members only.

The historical data trend for H. Lundbeck AS's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

H. Lundbeck AS Research & Development Chart

H. Lundbeck AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 514.11 504.60 463.81 603.54 655.39

H. Lundbeck AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 169.20 142.22 155.02 194.81 185.03
STU:LDBA
68GF Score
H. Lundbeck AS STU:LDBA
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

H. Lundbeck AS Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €677 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €677 Mil mean?
H. Lundbeck AS (STU:LDBA) has a Research & Development of €677 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on H. Lundbeck AS and its competitors.
Is H. Lundbeck AS's Research & Development too high?
H. Lundbeck AS's current Research & Development is €677 Mil. Overall, H. Lundbeck AS has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does H. Lundbeck AS's Research & Development compare to ZTS and UTHR?
H. Lundbeck AS's Research & Development of €677 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on H. Lundbeck AS and its competitors. H. Lundbeck AS's current Research & Development is €677 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is H. Lundbeck AS stock overvalued right now?
Based on GuruFocus' analysis, H. Lundbeck AS (STU:LDBA) is currently considered Modestly Undervalued. The stock's GF Value™ is €6.36, compared to a current price of €5.75 — trading 9.6% below its estimated fair value. The current Research & Development is €677 Mil. H. Lundbeck AS's overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For H. Lundbeck AS (STU:LDBA), the current Research & Development is €677 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is H. Lundbeck AS (STU:LDBA) Overvalued in 2026?

Based on GuruFocus' analysis, H. Lundbeck AS stock appears to be undervalued. The current stock price of €5.75 is trading 9.6% below its estimated GF Value™ of €6.36. GuruFocus considers H. Lundbeck AS to be Modestly Undervalued.

Key valuation signals for STU:LDBA:

  • Research & Development: €677 Mil
  • GF Value™: €6.36 vs. price of €5.75 (9.6% below fair value)
  • GF Score™: 68/100 with 3 warning signs

No single metric tells the full story. See the STU:LDBA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

H. Lundbeck AS Business Description

Address Ottiliavej 9, Valby, DNK, 2500
Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system drugs including antidepressants, antipsychotics, and antiepileptic products. The company's portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson's disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe.
68GF Score

Get the complete analysis for STU:LDBA

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.75
Price
€6.36
GF Value